AQ Trials adds governed AI to clinical research platform

AQ Trials has introduced Connected AI Intelligence, a governed AI layer for its clinical research platform that works from a single study record across core research systems. The company says the approach is meant to speed operations, reduce manual work and keep regulated decisions under human control.

Why it matters: - Clinical research teams face pressure to move faster while maintaining inspection readiness and regulatory control. - AQ Trials is positioning Connected AI Intelligence as a way to automate routine work without moving decision-making away from authorised staff. - The platform links operational data across study systems, which can surface risks earlier and reduce duplication across research workflows.

What happened: - AQ Trials introduced Connected AI Intelligence, a governed AI layer within the AQ Platform, on August 25, 2026. - The launch brings AI into clinical research operations through a connected, inspection-ready platform rather than isolated AI tools. - The system is built on a single study record shared across CTMS, eTMF, eISF, ePSF, QMS, CAPA and Digital Delegation of Authority modules. - The platform is designed to help NHS, academic and commercial research teams work from one continuously updated operational record.

The details: - Connected Intelligence analyzes relationships across the full study, not just within individual modules. - The AI is designed to forecast enrolment, recruitment and study milestones before delays occur. - The platform can identify site performance risks and operational bottlenecks earlier. - It can automatically organize, classify and retrieve study documentation. - It can detect missing essential documents, expiring certifications and incomplete records before inspections. - The system can generate monitoring reports, inspection summaries and operational narratives from existing study data. - It can predict protocol deviations, training gaps and recurring quality issues before they affect study delivery. - It can draft CAPAs, root cause analyses and quality documentation. - The platform can reconcile pharmacy inventory, dispensing records and investigational product accountability. - It continuously assesses inspection readiness across studies, sites and research networks. - AQ Trials says the system reduces repetitive administrative work so research teams can focus on participant care, study delivery and regulatory oversight. - The company said the platform evolved over six years through daily use across NHS, academic and commercial research. - AQ Trials said every AI recommendation is reviewable. - AQ Trials said every accepted action remains attributable to a named individual. - Electronic signatures, delegated responsibilities, record certification and study approvals still require human authorisation. - Every recommendation, decision and resulting action is permanently recorded in the platform's audit trail. - The company says the design supports validation in regulated research environments. - The platform is designed to support ICH-GCP E6(R3), the UK Clinical Trials Regulations, 21 CFR Part 11, ALCOA+, UK GDPR, NHS DSPT and Cyber Essentials. - AQ Trials says the platform combines connected operational data with governed AI assistance in clinical trial management software to improve inspection readiness, strengthen quality oversight and reduce operational burden. - AQ Trials is a clinical trial management platform that combines CTMS, eISF, ePSF, eTMF, QMS, CAPA and Digital DOA modules in one connected environment. - The company says the platform is designed to support alignment with ICH-GCP E6(R3), 21 CFR Part 11, EU Annex 11, GAMP 5, ALCOA+ and the NHS Data Security and Protection Toolkit. - More information is available at aq-trials.com.

Between the lines: - AQ Trials is framing AI as a governed assistive layer, not an autonomous decision-maker. - The emphasis on audit trails, named accountability and human approval reflects the stricter compliance demands in clinical research. - A single connected study record could reduce the friction that comes from managing research data across separate systems.

What's next: - AQ Trials is likely to push Connected Intelligence as a differentiator for organizations that want automation without weakening compliance controls. - The company will need to show that the AI improves speed and oversight in live study operations, not just in product messaging. - Broader adoption will depend on whether research teams trust the recommendations and can validate the outputs in regulated settings.

The bottom line: - AQ Trials is betting that clinical research teams want AI that prepares work, while people keep the final say on regulated decisions.